Skip to main content

Precipio, Inc.

corporate_fare Company Profile

Precipio, Inc.

PRPO·NASDAQ·Industrial Applications And Services·CIK 0001043961

Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly for hematologic malignancies, to combat disease misdiagnosis. The company aims to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. This is achieved through a combination of clinical laboratory services and proprietary diagnostic product development. Precipio's integrated operating structure allows its service business to function as a self-funded research and development (R&D) unit, enabling rapid and cost-efficient innovation. This structure allows the R&D team to evaluate, refine, and validate diagnostic products during routine clinical testing, generating clinical data, operational experience, and specimen access at incremental cost. Precipio operates with a single operating segment but has two complementary business divisions. The Pathology Services Division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. This division generates revenue and develops expertise in oncology diagnostics. It delivers specialized diagnostic testing primarily focused on hematologic cancers, including molecular diagnostics, cytogenetics, and related advanced laboratory analyses. Precipio receives patient samples, such as blood and biopsies, from clinics and hospitals, conducts diagnostic analyses, and provides pathology reports to physicians regarding the nature of the patient's disease.

Precipio, Inc. (NASDAQ:PRPO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 9 items for PRPO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for PRPO spans 10-Q, 4, 144, 8-K.

Recent high-impact activity:

  • Precipio Q3 10-Q: Record $7.3M Revenue, Yet Going Concern Doubt Persists
  • Precipio Posts Record $7.3M Quarterly Revenue, Turns GAAP Profitable
  • Precipio Q2 Revenue Jumps 24% but Going Concern Doubt Persists
  • Precipio Q2 Revenue Hits $7M, Up Sharply From Prior Year
  • Director Sells $77K in Shares Amidst Going Concern Warning

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$24.05M
Net Income
-$363K
Diluted EPS
-$0.23
Op. Cash Flow
$685K
Free Cash Flow
$359K
Gross Profit
$10.71M
Operating Income
-$1.2M
Cash & Equivalents
$2.65M
Total Debt
$77K
Debt / Equity
0.01×
Net Margin
-1.5%
Shares Outstanding
1.78M sh
Source: 10-K · filed 2026-03-30 · accession 0001104659-26-036878

Short Interest & Short Volume

1.47 days to cover

FINRA reported short interest of 54,907 shares in PRPO as of the October 30, 2026 settlement, a 6.7% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 19, 2026, 81.8% of PRPO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)54,907 shares as of October 30, 2026
Change vs prior period▼ 6.7%
Days to cover1.47 at avg daily volume of 37,269
Daily short volume (FINRA facilities)81.8% of 4,231 shares on November 19, 2026
5-day average short volume48.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$22.5
52-week range · as of 2026-11-10 $17.79 – $33.63
Market cap
$42.34M
Volume
17.7K (0.2× avg)
3-mo avg 99.1K
From SEC filing · 2026-11-10

show_chartPrice Chart

Loading chart...

feed PRPO - Latest Insights

PRPO
Nov 10, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
PRPO
Nov 10, 2026, 4:15 PM EST
Source: GlobeNewswire
Importance Score:
7
PRPO
Aug 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
PRPO
Aug 14, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
PRPO
May 21, 2026, 4:00 PM EDT
Filing Type: 4
Importance Score:
7
PRPO
May 19, 2026, 2:19 PM EDT
Filing Type: 144
Importance Score:
7
PRPO
May 14, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
9
PRPO
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
PRPO
Feb 27, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets